EyePoint Pharmaceuticals Grants Stock Options to New Employees Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals granted stock options to two new employees, allowing them to purchase up to 18,000 shares at $11.09 per share. The options vest over four years with a ten-year term. The inducement grants were made outside the company's 2023 Long-Term Incentive Plan, pursuant to NASDAQ Listing Rule 5635(c)(4).

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases, has announced the granting of non-statutory stock options to two new employees. The stock options, granted on August 15, 2025, allow the employees to purchase up to 18,000 shares of EyePoint common stock at an exercise price of $11.09 per share [1][2][3].

The grants were approved by the Compensation Committee and made as inducement material to each employee entering into employment with EyePoint, in accordance with NASDAQ Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant, and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint through the applicable vesting dates [1][2][3].

EyePoint's lead product candidate, DURAVYU™, is an investigational sustained delivery treatment for VEGF-mediated retinal diseases, combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. The company is committed to partnering with the retina community to improve patient lives while creating long-term value [1][2][3].

References:
[1] https://www.globenewswire.com/news-release/2025/08/18/3135290/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
[2] https://finance.yahoo.com/news/eyepoint-reports-inducement-grants-200100573.html
[3] https://www.stocktitan.net/news/EYPT/eye-point-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-pnuy91z0fo5k.html